Alterations in mRNA profiles of trastuzumab‑resistant Her‑2‑positive breast cancer

Molecular Medicine Reports
Bin ZhaoLi Li

Abstract

Breast cancer is one of the most common malignancies in women. Neoadjuvant trastuzumab therapy improves the prognosis of certain Her‑2‑positive breast cancer patients, however around two‑thirds of patients with Her‑2‑positive breast cancer do not benefit from Her‑2‑targeted therapy. To investigate the key mechanisms in trastuzumab resistance, potential biomarkers for neoadjuvant trastuzumab sensitivity were investigated using the gene expression omnibus (GEO) database for mRNA microarray data of Her‑2‑positive breast cancer patients who received neoadjuvant trastuzumab therapy. GEO profiles of 22 patients with a complete response and 48 patients with a partial response were identified in the GSE22358, GSE62327 and GSE66305 datasets. A total of 2,376, 1,000 and 1,152 differentially expressed genes in GSE22358, GSE62327 and GSE66305 datasets were demonstrated, respectively, utilizing GEO2R software. Furthermore, enriched gene ontology terms and Kyoto Encyclopedia of Genes and Genomes pathways were analyzed using the Database for Annotation, Visualization and Integrated Discovery software. Subsequently, a protein‑protein interaction network was established using STRING software. The results demonstrated that low sex‑determining re...Continue Reading

References

Mar 31, 2000·Nature Medicine·R A ClynesJ V Ravetch
Jan 15, 2003·BMC Bioinformatics·Gary D Bader, Christopher W V Hogue
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Dec 31, 2005·Annals of the New York Academy of Sciences·Keng-Hsueh LanDihua Yu
Mar 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Valentina GuarneriAna M Gonzalez-Angulo
Nov 14, 2006·Breast Cancer Research : BCR·Rita Nahta, Francisco J Esteva
Mar 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael UntchGunter von Minckwitz
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Oct 14, 2011·The New England Journal of Medicine·Dennis SlamonUNKNOWN Breast Cancer International Research Group
Dec 14, 2011·Current Pharmacogenomics and Personalized Medicine·Anatasha Crawford, Rita Nahta
Jun 30, 2012·Virchows Archiv : an International Journal of Pathology·Mattia BarbareschiPaolo Dalla Palma
Nov 30, 2014·Molecular and Cellular Endocrinology·Bo HuangJan-Åke Gustafsson
Apr 10, 2015·Asian Pacific Journal of Cancer Prevention : APJCP·Kerem OkuturGokhan Demir
May 28, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mario GiulianoRachel Schiff
Oct 11, 2015·Current Cancer Drug Targets·Otília MenyhartBalazs Gyorffy
Oct 11, 2016·Journal of breast cancer·Yong Hwa EomByung Joo Chae
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Feb 22, 2017·Pharmacology & Therapeutics·Nandini DeyBrian Leyland-Jones
Mar 2, 2017·Journal of Cancer Research and Clinical Oncology·Mateus de Oliveira TaveiraGerburg M Wulf
Apr 7, 2017·Journal of breast cancer·Ki-Tae HwangDong-Young Noh

❮ Previous
Next ❯

Datasets Mentioned

BETA
GSE62327
GSE66305

Methods Mentioned

BETA
chips

Software Mentioned

DAVID
MCODE
Molecular Complete Detection ( MCODE
Venn Diagrams
Cytoscape
Search Tool for the Retrieval

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.